Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPRNASDAQ:CNTANASDAQ:IDYANASDAQ:SUPN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$13.18+6.8%$10.23$3.52▼$23.40$602.02M0.851.77 million shs2.77 million shsCNTACentessa Pharmaceuticals$11.86-5.3%$12.59$8.46▼$19.09$1.58B1.48675,302 shs3.56 million shsIDYAIDEAYA Biosciences$21.10$18.11$13.45▼$44.42$1.85B0.261.02 million shs719,178 shsSUPNSupernus Pharmaceuticals$32.34+0.1%$31.92$25.53▼$40.28$1.81B0.74481,219 shs296,078 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics+6.81%+30.62%+79.71%+2.89%+134.52%CNTACentessa Pharmaceuticals-5.35%-9.26%-1.13%-26.93%+34.77%IDYAIDEAYA Biosciences0.00%+5.24%+18.87%+14.30%-46.80%SUPNSupernus Pharmaceuticals+0.12%+2.08%-0.28%+0.84%+17.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPRCapricor Therapeutics1.8013 of 5 stars3.51.00.00.02.60.80.6CNTACentessa Pharmaceuticals3.1633 of 5 stars4.51.00.00.01.93.30.6IDYAIDEAYA Biosciences3.6573 of 5 stars3.52.00.04.41.91.70.0SUPNSupernus Pharmaceuticals2.26 of 5 stars2.21.00.04.12.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 3.00Buy$35.50169.35% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.89135.15% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27157.22% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0011.32% UpsideCurrent Analyst Ratings BreakdownLatest CAPR, IDYA, CNTA, and SUPN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025CNTACentessa PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/20/2025CAPRCapricor TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$31.005/14/2025CAPRCapricor TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.005/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/20/2025CAPRCapricor TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.003/17/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$77.00 ➝ $77.003/7/2025CNTACentessa PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$27.00 ➝ $27.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$17.36M34.67N/AN/A$0.73 per share18.05CNTACentessa Pharmaceuticals$15M105.60N/AN/A$2.42 per share4.90IDYAIDEAYA Biosciences$7M264.00N/AN/A$12.10 per share1.74SUPNSupernus Pharmaceuticals$668.00M2.71$1.48 per share21.83$16.87 per share1.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$22.29M-$1.42N/AN/AN/A-146.86%-112.95%-57.00%8/6/2025 (Estimated)CNTACentessa Pharmaceuticals-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%8/12/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)SUPNSupernus Pharmaceuticals$1.32M$1.1130.2222.46N/A9.16%7.79%5.67%8/5/2025 (Estimated)Latest CAPR, IDYA, CNTA, and SUPN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CAPRCapricor Therapeutics-$0.33-$0.53-$0.20-$0.53$3.16 million$2.73 million5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/A3/19/2025Q4 2024CAPRCapricor Therapeutics-$0.31-$0.16+$0.15-$0.16$9.87 million$11.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A4.194.19CNTACentessa Pharmaceuticals0.1521.5221.52IDYAIDEAYA BiosciencesN/A14.9722.93SUPNSupernus PharmaceuticalsN/A2.201.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%CNTACentessa Pharmaceuticals82.01%IDYAIDEAYA Biosciences98.29%SUPNSupernus PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics10.50%CNTACentessa Pharmaceuticals7.09%IDYAIDEAYA Biosciences2.50%SUPNSupernus Pharmaceuticals8.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor TherapeuticsN/A45.68 million40.01 millionOptionableCNTACentessa Pharmaceuticals200133.56 million116.56 millionOptionableIDYAIDEAYA Biosciences8087.58 million84.47 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million50.08 millionOptionableCAPR, IDYA, CNTA, and SUPN HeadlinesRecent News About These CompaniesHennion & Walsh Asset Management Inc. Acquires 11,304 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5 at 5:20 AM | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.62 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5 at 4:05 AM | marketbeat.comMillennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)June 5 at 3:24 AM | marketbeat.comBranded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)June 2, 2025 | msn.comJefferies Financial Group Inc. Buys Shares of 24,600 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 31, 2025 | marketbeat.comVoloridge Investment Management LLC Cuts Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 31, 2025 | marketbeat.comSupernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with QelbreeMay 29, 2025 | quiverquant.comJay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus PharmaceuticalsMay 29, 2025 | globenewswire.comSupernus to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comSupernus Announces Paragraph IV ANDA Filings for Qelbree®May 28, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), 908 Devices (MASS) and Supernus Pharmaceuticals (SUPN)May 24, 2025 | theglobeandmail.comWoodline Partners LP Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Buys Shares of 26,828 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 24, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Deutsche Bank AGMay 22, 2025 | marketbeat.comSupernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHDMay 20, 2025 | quiverquant.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Systematic Financial Management LPMay 20, 2025 | marketbeat.comCaptrust Financial Advisors Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 20, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Ameriprise Financial Inc.May 19, 2025 | marketbeat.comJefferies Financial Group Inc. Buys New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 18, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Polar Capital Holdings PlcMay 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $19.73 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)May 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCAPR, IDYA, CNTA, and SUPN Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$13.18 +0.84 (+6.81%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$13.27 +0.09 (+0.69%) As of 06/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Centessa Pharmaceuticals NASDAQ:CNTA$11.86 -0.67 (-5.35%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$12.21 +0.35 (+2.94%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.IDEAYA Biosciences NASDAQ:IDYA$21.10 0.00 (0.00%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$21.10 0.00 (0.00%) As of 06/5/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Supernus Pharmaceuticals NASDAQ:SUPN$32.34 +0.04 (+0.12%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$33.25 +0.91 (+2.81%) As of 06/5/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
